- Home
- BAH vs GMAB Comparison
BAH vs GMAB Comparison
Compare BAH & GMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BAH
- GMAB
- Stock Information
- Founded
- BAH 1914
- GMAB 1999
- Country
- BAH United States
- GMAB Denmark
- Employees
- BAH N/A
- GMAB N/A
- Industry
- BAH Professional Services
- GMAB Biotechnology: Pharmaceutical Preparations
- Sector
- BAH Consumer Discretionary
- GMAB Health Care
- Exchange
- BAH Nasdaq
- GMAB Nasdaq
- Market Cap
- BAH 13.9B
- GMAB 13.7B
- IPO Year
- BAH 2010
- GMAB N/A
- Fundamental
- Price
- BAH $106.88
- GMAB $21.45
- Analyst Decision
- BAH Hold
- GMAB Buy
- Analyst Count
- BAH 12
- GMAB 8
- Target Price
- BAH $135.09
- GMAB $37.80
- AVG Volume (30 Days)
- BAH 1.9M
- GMAB 1.6M
- Earning Date
- BAH 07-25-2025
- GMAB 08-07-2025
- Dividend Yield
- BAH 2.06%
- GMAB N/A
- EPS Growth
- BAH 57.95
- GMAB 276.80
- EPS
- BAH 7.25
- GMAB 18.36
- Revenue
- BAH $11,980,000,000.00
- GMAB $3,230,902,140.00
- Revenue This Year
- BAH $3.69
- GMAB $747.74
- Revenue Next Year
- BAH $4.89
- GMAB $14.81
- P/E Ratio
- BAH $14.75
- GMAB $1.17
- Revenue Growth
- BAH 12.36
- GMAB 25.43
- 52 Week Low
- BAH $98.95
- GMAB $17.24
- 52 Week High
- BAH $190.59
- GMAB $28.56
- Technical
- Relative Strength Index (RSI)
- BAH 50.66
- GMAB 53.47
- Support Level
- BAH $105.83
- GMAB $20.23
- Resistance Level
- BAH $109.22
- GMAB $21.90
- Average True Range (ATR)
- BAH 2.41
- GMAB 0.35
- MACD
- BAH 0.91
- GMAB 0.06
- Stochastic Oscillator
- BAH 67.37
- GMAB 73.52
About BAH Booz Allen Hamilton Holding Corporation
Booz Allen Hamilton Holding Corp is a provider of management consulting services to the U.S. government. Other services offered include technology, such as cloud computing and cybersecurity consulting, and engineering consulting. The consulting services are focused on defense, intelligence, and civil markets. In addition to the U.S. government, Booz Allen Hamilton provides its management and technology consulting services to large corporations, institutions, and nonprofit organizations. The company assists clients in long-term engagements around the globe.
About GMAB Genmab A/S ADS
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.